Detalles de la búsqueda
1.
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
BMC Cancer
; 19(1): 504, 2019 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-31138244
2.
Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation.
Haematologica
; 102(8): 1432-1438, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28495913
3.
Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial.
Br J Haematol
; 173(5): 731-41, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26990892
4.
Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients.
Haematologica
; 106(10): 2754-2758, 2021 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34092058
5.
High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.
Blood
; 121(4): 624-7, 2013 Jan 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-23233657
6.
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
Haematologica
; 100(7): 964-9, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25840597
7.
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.
Blood
; 119(4): 940-8, 2012 Jan 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-22160383
8.
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.
Haematologica
; 99(1): 148-54, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23996482
9.
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.
Leukemia
; 38(3): 640-647, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38062124
10.
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.
Lancet Haematol
; 11(2): e101-e113, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38302221
11.
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma.
Blood Cancer J
; 13(1): 1, 2023 01 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36599831
12.
RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma.
Front Immunol
; 14: 1286700, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38035078
13.
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.
Blood
; 116(14): 2543-53, 2010 Oct 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-20574050
14.
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.
Blood Adv
; 6(2): 515-520, 2022 01 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-34768284
15.
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.
J Clin Oncol
; 40(29): 3406-3418, 2022 10 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35605179
16.
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Lancet Haematol
; 9(11): e810-e821, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36328040
17.
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.
Blood
; 113(19): 4614-26, 2009 May 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-19228610
18.
Induction of angiogenesis by normal and malignant plasma cells.
Blood
; 114(1): 128-43, 2009 Jul 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-19299335
19.
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma.
Blood
; 113(18): 4331-40, 2009 Apr 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-19171872
20.
Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma.
Haematologica
; 101(3): e116-9, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26611471